Rituxan Could Be Top Source Of Price Inflation Rebates In Medicare Part B
Executive Summary
HHS Office of Inspector General estimates $1.4bn to $1.8bn could have been saved in Medicare Part B in 2015 if manufacturers provided rebates when drug prices increased faster than inflation.